All In Biotech

BLA 020032 · Abbvie

Survanta

Beractant · Intratracheal · Surfactant

NovelOrphan

Last checked: Nov 19, 2026Latest source record: Jul 15, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Jul 1, 1991

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

4 Phase 3, 0 recruiting

FAERS reports

369

362 serious, 222 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 15, 2020.

INDICATIONS AND USAGE SURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 1, 1991 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • SURVANTA · BERACTANT 25MG/ML · SUSPENSION, INTRATRACHEAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Beractant" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pulmonary haemorrhage126
  • death54
  • neurodevelopmental disorder36
  • pneumothorax34
  • drug ineffective33
  • sepsis19
  • neonatal respiratory distress syndrome17
  • endotracheal intubation complication16
  • neonatal disorder16
  • oxygen saturation decreased16
  • respiratory failure15
  • acute respiratory distress syndrome14

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200518
20065
20073
200812
20098
20105
201118
201215
201333
201470
201515
201617
201733
201827
201916
202016
20218
202212
20248
202510
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 83 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.